Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure

摘要: Background and Aims:  Chronic hepatitis B virus (HBV) infection is a major global health issue, the prognosis of patients with HBV-associated acute-on-chronic hepatic failure (ACLF) extremely poor. In this study, efficacy lamivudine was investigated in ACLF. The effects HBV DNA load its related factors on were also further explored. Methods:  A matched retrospective cohort study using data ACLF derived from our hospital database conducted. One hundred thirty receiving selected into treatment group another 130 without studied as control. They for sex, age imaging finding group. All followed up 3 months survival rates compared. influential mortality by Cox proportional hazards model. Results:  cumulative higher than those control (χ2 = 9.50, P = 0.0021). high (71/95, 74.7%) that low (15/29, 51.7%) (χ2 = 5.536, P = 0.019). For Model End-Stage Liver Disease (MELD) score 20–30 week 4, undetectable or declined more 2 log10 (2/12, 16.7%; 18/40, 45.0%) lower less 2 log10 decline (18/23, 78.3%) (χ2 = 10.106, P = 0.001). model, MELD 20–30, method (P = 0.002), pretreatment (P = 0.007) during therapy (P = 0.003) independent predictors; above 30, (P = 0.008) only predictor. Conclusion:  Lamivudine can significantly decrease 3-month viral rapid are good predictors outcome treatment.